Bilateral hand squamous-cells carcinoma in patient affected with non-Hodgkin lymphoma Case report and literature review

Fino, Pasquale; Spagnoli, Alessandra; Ruggieri, M; Marcasciano, Marco; Scuderi, Nicolò

doi:10.11138/gchir/2015.36.4.172

Cited by 4 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Squamous cell carcinoma is a malignancy of squamous cells involving areas of cutaneous frequently exposed to ultraviolet radiation (UV radiation) such as the face, ears and hands. Although it is the second most common nonmelanoma skin carcinoma after basal cell carcinoma, it is the most common cutaneous malignancy of the hand (2,3). It commonly manifests as a scaly, reddish patch of skin that slowly evolves into a raised macule, which may crust and bleed.…”

Section: Discussionmentioning

confidence: 99%

Squamous Cell Carcinoma of the Finger Nail Bed: An Onychomycosis Like Lesion

Nagaretnam¹,

Looi²

2023

MJMHS

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Squamous Cell Carcinoma of the Finger Nail Bed: An Onychomycosis Like Lesion

Nagaretnam¹,

Looi²

2023

MJMHS

View full text Add to dashboard Cite

show abstract

“…Lymphoma is a type of malignant tumor derived from the lymph and hematopoietic systems, including the subtypes of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (1,2). Although HL and NHL are all neoplastic diseases of lymphoid tissues, the clinical manifestations and histopathology is in contrast.…”

Section: Introductionmentioning

confidence: 99%

Tumor necrosis factor receptor 2 may promote the proliferation and drug resistance of Kapras299 and L428 lymphoma cells via the AKT and WNT/β‑catenin signaling pathways

et al. 2018

View full text Add to dashboard Cite

Circulating soluble tumor necrosis factor receptor 2 (sTNFR2) has been associated with a relatively poor prognosis in various types of lymphoma. However, the specific role of TNFR2 expression in lymphoma cells remains uncharacterized. In the present study, TNFR2 expression was quantified in the Hodgkin lymphoma cell line, L428, and the anaplastic large-cell lymphoma cell line, Karpas299, using RT-PCR and western blot analyses. Karpas299 cells exhibited higher TNFR2 expression than L428 cells. Proliferation and drug resistance experiments demonstrated that Karpas299 cells also possessed a greater proliferative ability and resistance to adriamycin (ADM) than L428 cells, with 50% inhibitory concentrations (IC) of 1.423±0.24 µmol/l for Karpas299 cells, compared with 0.728±0.15 µmol/l for L428 cells (P<0.05). The knockdown of TNFR2 in Karpas299 cells significantly reduced their proliferative ability; when treated with ADM, the cell inhibition rate increased from 49.34±5.42% to 74.13±6.81% (P<0.05). The upregulation of TNFR2 in L428 cells significantly increased their proliferative ability; when treated with ADM, the cell inhibition rate decreased from 47.03±5.25% to 28.71±4.90% (P<0.05). Investigation of the underlying molecular mechanism indicated that the upregulation of TNFR2 expression in L428 cells increased the expression of β-catenin and the phosphorylation of AKT. In L428 cells overexpressing TNFR2, the β-catenin blocker, DKK1, or the AKT inhibitor, LY294002, abrogated the increase in proliferation induced by TNFR2 and increased cell inhibition rate upon treatment with ADM. In summary, the present study demonstrated that TNFR2 promoted the proliferative and drug resistance abilities of lymphoma cells via the AKT and WNT/β-catenin signaling pathways. This may provide the experimental basis for the further study of TNFR2 activity in lymphoma cells and warrant its investigation as a therapeutic target for lymphoma.

show abstract